ALX1-transcribed LncRNA AC132217.4 Promotes Osteogenesis and Bone Healing via IGF-AKT Signaling in Mesenchymal Stem Cells

cui Zhang

Zhejiang University Life Science Institute

Shali Wu

Zhejiang University Life Science Institute

Erman Chen

Zhejiang University School of Medicine

Luyang Yu

Zhejiang University Life Science Institute

Jinfu Wang

Zhejiang University Life Science Institute

Mengrui Wu (✉ mengruiwu@zju.edu.cn)

Zhejiang University <https://orcid.org/0000-0003-1059-0916>

Research Article

Keywords: lncRNA, bone marrow mesenchymal stem cells, osteogenic differentiation, IGF2, bone regeneration

Posted Date: February 21st, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1364413/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

The osteogenic potential of bone marrow mesenchymal stem cells (BMSCs) is critical for bone formation and regeneration. A high non-/delayed-union rate of fracture healing still occurs in specific populations, implying an urgent need to discover novel targets for promoting osteogenesis and bone regeneration. Long non-coding (lnc)RNAs are emerging regulators of multiple physiological processes, including osteogenesis. Based on differential expression analysis of RNA sequencing data, we found that lncRNA AC132217.4, a 3'UTR-Overlapping lncRNA of insulin growth factor 2 (IGF2), was highly induced during osteogenic differentiation of BMSCs. Afterward, both gain-of-function and loss-of-function experiments proved that AC132217.4 promotes osteoblast development from BMSCs. As for its molecular mechanism, we found that AC132217.4 binds with *IGF2* mRNA to regulate its expression and downstream AKT activation to control osteoblast maturation and function. We also identified two splicing factors from RNA-pull-down assay, serine and arginine-rich splicing factor 2 (SRSF2) and heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1) regulates AC132217.4 biogenesis at post-transcriptional level. Furthermore, we identified a transcription factor, ALX1, regulates AC132217.7 expression at transcriptional level to promote osteogenesis. Importantly, *in-vivo* over-expression of AC132217.4 essentially promotes the bone healing process in a murine tibial drill-hole model. Altogether, our study demonstrates that lncRNA AC132217.4 is a novel anabolic regulator of BMSC osteogenesis and could be a plausible therapeutic target for improving bone regeneration.

Introduction

Mesenchymal stem cells (MSCs) derived from adult tissues, such as bone marrow and umbilical cord blood, can differentiate into various cell types, including osteoblasts, chondrocytes, and adipocytes.(1–5) The osteogenic potential of MSCs is critical for bone formation and regeneration since osteoblasts are the principal cells that generate bone matrix.(6–8) Delay or failure of bone repair results in pain and physical disabilities, which severely impair the life quality of the patients.(9, 10) Current strategies to accelerate bone regeneration include applying growth factors, bone marrow aspirates, and scaffolds locally to the fracture sites.(2, 9, 10) However, a significant non-union or delayed union rate still occurs, especially in aging populations (10–25%)(9) and diabetic patients (43%)(11, 12). Thus, the development of a more efficient treatment for bone regeneration is desperately needed.

lncRNAs, typically > 200bp, were initially annotated as non-functional spurious RNAs, and closer examination of lncRNA properties reveals their functionality and diversity.(13–16) A few lncRNAs have been reported to participate in the process of MSC differentiation, and some specifically regulate the osteogenesis of MSCs or fracture healing.(17–22) However, the functions of most lncRNAs during MSC osteogenic differentiation remain largely unknown. Therefore, elucidating the role of novel lncRNAs in regulating the osteogenesis of MSCs might facilitate the development of novel treatments for bone diseases. Compared to mRNAs, expression of lncRNAs are more specific in a developmental stage- or disease status- specific manner, and genome sequences of lncRNA usually contain weaker transcription

and splicing signals, indicating that their biogenesis requires more tight regulations.(23–25) However, the regulatory mechanism of lncRNA AC132217.4 is barely studied in bone.

This study found that lncRNA AC132217.4 is a novel osteogenic factor in MSC. AC132217.4 was an IGF2 3'UTR overlapped lncRNA, and has been shown to facilitate oral squamous cell carcinoma metastasis(26). However, the role of AC132217.4 in bone was not previously reported. We found that AC132217.4 expression is highly upregulated during MSC osteogenesis, and demonstrated that it enhances osteogenic differentiation through the IGF-AKT signaling axis. To explore the biogenesis mechanism of AC132217.4, we performed RNA-pull down and promoter analysis, and found that AC132217.4 expression is cooperatively controlled by the transcriptional factor, ALX1, and two splicing factors, SRSF2 and HNRNPA1. Importantly, we also showed AC132217.4 overexpression in mice promotes bone healing. Our findings might offer new treatment options for bone repair.

Material And Methods

Isolation and osteogenic induction of hBMSCs

hBMSCs were isolated from whole bone marrow samples collected from healthy donors at the Second Affiliated Hospital, Zhejiang University, after obtaining informed consent, as previously described(27). Cells at the third passage were plated at 60–70% confluence and cultured in the osteogenic differentiation medium (L-Dulbecco's modified Eagle's medium [Life Technologies Inc., China] supplemented with 10% fetal bovine serum, 50µg/mL L-ascorbic acid, and 10mM β-sodium glycerophosphate [Sigma Inc., China]).

RNA-protein pull-down

Biotin-labeled AC132217.4 and AC132217.4 pre-RNA were transcribed *in vitro* using the MEGAscript T7 kit and purified lithium chloride. Purified RNA was incubated with the protein lysis product, and RNA pull-down was conducted using Pierce™ magnetic RNA-protein pull-down kit (Life Technologies Inc., China). The combined proteins and pre-RNA of AC132217.4 were confirmed using silver staining with the Silver staining kit (Beyotime Biotech Inc., China), mass spectrometry (MS), and western blotting.

Tibial drill-hole murine model

The tibial drill-hole murine model for studying bone repair was established as previously described. (28,29) Briefly, mice were anesthetized with an intraperitoneal injection of 1% pentobarbital sodium solution (75 mg/kg body weight), and the right hindlimb was shaved and sterilized. Afterward, a 1-mm diameter hole was made in the cortical bone of the anterior proximal tibia of 3-month-old male C57BL/6 mice using an electronic drill. The muscle and skin were closed with layered sutures.

The control and experimental groups were administered 50µL lentivirus (109 TU/mL), carrying green fluorescent protein (GFP) or AC132217.4, respectively, near the cortical hole for three consecutive days post-surgery. Each group comprised eight mice euthanized for tissue harvesting 7 and 14 days after the

surgery. All the mice were housed at 20°C–22°C on a 12hr light/dark cycle in the institutional animal facility of the Zhejiang University. All animal studies were approved by the Institutional Animal Care and Use Committee (IACUC) and were performed following the Guide for the Care and Use of Laboratory Animals.

Statistical analysis

Results are expressed as mean $\pm$ standard error of the mean (SEM). Statistical significance was determined using the Student's *t*-test or two-way analysis of variance followed by post hoc Bonferroni correction, and significance was set at *p*-value < 0.05.

More details of Materials and Methods are available in the supplemental files.

Results

LncRNA AC132217.4 promotes osteogenic differentiation of hBMSCs

To identify novel lncRNA regulators of osteogenic differentiation of hBMSCs, the lncRNA expression profiles of primary and osteogenic-differentiated hBMSCs were compared using RNA sequencing analysis. The data are deposited in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus and are accessible through GEO Series accession number GSE114117 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi>). We observed a dramatic increase in lncRNA AC132217.4 among these altered lncRNAs during osteogenic differentiation of hBMSC (Fig. 1A, S1A), which was subsequently confirmed using qRT-PCR analysis with primers specific to AC132217.4 (Fig. 1B).

To validate the role of AC132217.4 during osteogenic differentiation of hBMSCs, we over-express and knockdown AC132217.4 expression in hBMSCs, respectively. Osteogenic differentiation was induced in control and AC132217.4-overexpressing hBMSCs for seven days (Fig. S1B). AC132217.4 overexpression up-regulates osteoblast marker gene expression, indicating that AC132217.4 promotes osteogenesis. AC132217.4-overexpressing cells showed increased *ALP*, *COL 1A1*, and *RUNX2* mRNA level (Fig. 1C), as detected by qPCR and elevated COL1A1 and OCN protein level (Fig. 1D), as shown by western blot. The ALP and alizarin red stain consistently showed osteoblast maturation and mineralization increased in AC132217.4-overexpressing cells (Fig. 1E–G). Conversely, knocking down of AC132217.4 in hBMSCs (Fig. S1C) decreased *ALP*, *COL 1A1*, and *RUNX2* mRNA expression (Fig. 1H), reduced COL1A1 and OCN protein levels (Fig. 1I), and impaired ALP activity and mineralized nodule formation (Fig. 1J–L).

AC132217.4 promoted osteogenic differentiation of hBMSCs via IGF2/AKT signaling

To investigate the mechanism underlying AC132217.4 regulating osteogenic differentiation of hBMSCs, we performed RNA pull-down coupled with MS using synthesized AC132217.4 (Fig. 2A–C). Unfortunately, none of the five proteins interacting with AC132217.4 seem to function in osteogenic differentiation (Fig. 2C). Thus, we speculated that lncRNA AC132217.4 might exert its role by interacting with nucleotides

rather than proteins (Fig. 2A-C, S2A). To determine whether AC132217.4 binds to DNA or RNA, we examined the cellular location of AC132217.4. We found that its distribution was restricted to the cytoplasm rather than nuclear compartments, as observed in the FISH analysis and cell fractionation (Fig. 2D, E). Therefore, it is likely that AC132217.4 is binding to RNA rather than DNA in the cytoplasm. Grounded on this assumption, we predicted potential targeted mRNA by AC132217.4 using Starbase (Fig. S2B), and the *IGF2* mRNA showed the highest align score.

To test whether AC132217.4 regulates the expression of IGF2 to mediate osteogenesis, we first compared the expression pattern of IGF2 to that of lncRNA AC132217.4 in our RNA-seq dataset. We found that they were similar (Fig. S2C). As confirmed by qPCR and western blot, the expression of IGF2 in hBMSCs subjected to osteogenic induction was consistently up-regulated (Fig. 2F, G). Then we test whether AC132217.4 over-expression or knockdown impacts IGF2 abundance during osteogenic differentiation (Fig. 2I-K). As expected, the level of IGF2 mRNA was remarkably up-regulated in AC132217.4-overexpressing cells and down-regulated in AC132217.4-knockdown cells. Then we examined whether AC132217.4 affects IGF2 mRNA stability after transcription. hBMSCs induced osteogenesis for seven days were treated with actinomycin D (ActD) to block the *de novo* mRNA synthesis to examine IGF2 mRNA stability. The IGF2 mRNA stability increased in AC132217.4 over-expressing cells (Fig. 2H). IGF1 promotes osteoblast formation and bone development through AKT signalling(30,31). While IGF2's function was less known, the previous study also supports its anabolic roles in osteogenesis(32-34). To confirm the role of IGF2 in osteogenic differentiation, we knock down IGF2 expression in MSCs, using lentivirus carrying the shRNA targeting IGF2 (sh-IGF2) (Fig. S2D). sh-IGF2 downregulates osteoblast marker gene expression at both RNA and protein levels, as shown by qPCR and western blot (Fig. 3A, B). sh-IGF2 also inhibits osteoblast maturation and mineralization, as shown by ALP and Alizarin red stains, respectively (Fig. 3C-E). Those data prove that IGF2 promotes osteogenic differentiation just like AC132217.4. Significantly, IGF2 knockdown can suppress the overwhelming osteogenesis induced by AC132217.4 overexpression, as demonstrated by osteoblast marker gene expression (Fig. 3F, G), as well as ALP and Alizarin red stains (Fig. 3H-J). These data indicate that IGF2 is the critical downstream effector of AC132217.4 in the osteoblast. We next investigated the possible downstream mechanisms underlying the AC132217.4-IGF2 axis. AKT phosphorylation increased with AC132217.4 over-expression, whereas IGF2 knockdown ablated the increase (Fig. 3K, L). Collectively, our data suggest that AC132217.4 confers bone anabolic properties through AKT signaling downstream of IGF2.

HNRNPA1 and SC35 promoted lncRNA AC132217.4 splicing and expression

AC132217.4 is a novel, 3'UTR-overlapping lncRNA of *IGF2*, spliced from an 844 bp gene segment, in the *Ensembl database* (Fig. S3A). RT-PCR using flanking primers gives out a band indicating a spliced product of the expected size (4A, B). To confirm the splice sites of AC132217.4, we mutated them in its pre-RNA (Fig. S3B) and overexpressed the wild-type and mutated pre-RNA in hBMSCs. Overexpression of site-mutated pre-RNA leads to much less production of AC132217.4 compared to the wild-type pre-RNA (Fig. 4C). Then all existing splicing sites in the pre-RNA of AC132217.4 were predicted *in silico* using the NetGene2. Notably, compared with the highest-ranked splice site, AC132217.4 splice site yields a much

lower splice site value (0.43 compared with 0.66) (Fig. S3C). Nevertheless, AC132217.4 is still a major product spliced from its pre-RNA; This indicates that alternative splicing mechanisms alter the splice site preference to favor the production of AC132217.4. Within the protein list derived from RNA pull-down using AC132217.4 pre-RNA (Fig.2A), we found two splice regulators, HNRNPA1 and SC35, obtained the highest score (Fig 4D). The donor and acceptor splice sites of AC132217.4 in its pre-RNA were also consistent with the binding motif of HNRNPA1 and SC35 (Fig. S3D). RNA pull-down and western blotting results confirmed the binding of HNRNPA1 and SC35 with the pre-RNA of AC132217.4 (Fig. 4E). To confirm that HNRNPA1 and SC35 bind with AC132217.4 pre-RNA and are functionally involved in the splicing of lncRNA AC132217.4, we knockdown SC35 or HNRNPA1 expression respectively in the BMSCs using shRNA (Fig. 4F), and both markedly reduced the expression of AC132217.4 (Fig. 4G).

ALX1 regulated osteogenic differentiation of hBMSCs by promoting AC132217.4 expression

To uncover the molecular mechanism, control the increased transcription of AC132217.4 during osteogenic differentiation of hBMSCs, we searched for transcription factors with a similar expression pattern as AC132217.4. In our RNA-seq dataset, we found 12 up-regulated and 17 down-regulated transcription factors (Fig. 5A). To determine which of the 29 candidates are involved in the transcription of AC132217.4, we analyze the binding partners on the AC132217.4 promoter, a ~3000-bp genomic region upstream of AC132217.4, using PROMO. PROMO predicted eight highly-ranked ALX1 binding sites in the promoter region of AC132217.4 (Fig. 5B, C). These results indicate that ALX1 could be the transcription factor regulating the expression of AC132217.4. To confirm this, we knocked down ALX1 expression using two independent shRNAs, which efficiently reduced the mRNA and protein levels of ALX1 in hBMSCs. Compared to the control, ALX1 knockdown significantly decreased the expression of AC132217.4 and IGF2 (Fig. 5D, E). Conversely, ALX1 over-expression markedly elevated AC132217.4 and IGF2 expression (Fig. 5F, G). We further showed that ALX1 drives luciferase expression under the control of the promoter region of AC132217.4, whereas this effect was abolished by mutation of the ALX1 consensus sequences in the promoter region (Fig. 5H, I). This piece of data indicated that ALX1 could drive AC132217.4 at the transcriptional level. Overexpression of ALX1 also increased IGF2 expression (Fig. 5J), which could be reversed by AC132217.4 knockdown (Fig. 5K). These data imply that the ALX1 controls AC132217.4 transcription, which in turn regulates IGF2 expression.

Importantly, we found ALX1 overexpression is promoting osteoblast differentiation, which could be compromised by knockdown of either AC132217.4 or IGF2 (Fig. 6). ALX1 overexpression promoted osteoblast differentiation and maturation, as confirmed by ALP stain and alizarin stain, respectively, both of which could be suppressed by either IGF2 or AC132217.4 knockdown (Fig. 6A,B). ALX1 overexpression is promoting osteoblast gene expression, as detected by qPCR and western blot, which could be also compromised by knockdown of either AC132217.4 or IGF2 (Fig. 6C,D).

AC132217.4 promoted bone repair in mice

To evaluate the effects of AC132217.4 on osteoblast differentiation in *vivo* and bone regeneration, we manipulated AC132217.4 expression using lentivirus carrying AC132217.4 in a tibia drill-hole murine

model (Fig. 7A). (28,29) Since the lentiviral vectors comprise a GFP-expressing element, we confirmed their infection rate by tracing GFP expression (Fig. 7B). A natural healing process goes through several stages, including inflammation, cartilaginous callus formation, bony callus formation, and bone remodeling(35). To analyze bone healing at different stages, we harvested tissues 1- and 2-weeks post-surgery.

As shown by μ -CT, one week post-surgery, both bone fraction (BV/TV) and bone mineral density (BMD) were significantly higher in AC132217.4 over-expressing bone healing site, $2.675\% \pm 0.48\%$, and $1.5\% \pm 0.32\%$ respectively as compared to control (Fig. 7C, D). Two weeks post-surgery, AC132217.4 overexpression still elevated BV/TV and BMD ($1.995\% \pm 0.08\%$ and $1.9125\% \pm 0.385\%$ respectively), albeit not significantly (Fig. 7C, D). As shown by reconstructed three-dimensional images (Fig. 7C) and H&E stain (Fig. 7E), control bone marrow at the healing site was stuffed with woven bones two-week post-surgery (Fig. 7D). On the contrary, at the AC132217.4-overexpressing healing site, new bones were refined in the cortical area; Woven bones were already remodeled and cleared, with a reasonable reduction of callus tissue volume at the same stage. These data indicate that AC132217.4 promotes the transition from soft callus to hard callus and accelerates bone remodeling.

The histological analysis (Fig. 7E-G) confirmed the abovementioned findings. As shown by H&E (Fig. 7E) and *Safranin O* staining (Fig. 7F), one-week post-surgery, AC132217.4-overexpressing bone healing sites were predominantly bony callus; whereas the control group is still in the cartilaginous callus formation stage. Two weeks post-surgery, the bony callus/cartilaginous callus ratio was still much higher in the AC132217.4-overexpressing group (Fig. 7E, F). TRAP staining showed more osteoclast in the AC132217.4-overexpressing group than the control group one week post-surgery (Fig. 7G). Increasing osteoclast number was not observed in the control group until two-week post-surgery (Fig. 7G), indicating its remodeling stage is one week lagged compared to the AC132217.4-overexpressing group. Overall, these results demonstrate AC132217.4 overexpression largely fastens multiple processes during bone regeneration.

Discussion

AC132217.4 is a novel lncRNA regulator of MSC osteogenesis

Many lncRNA were identified to be functional during the last decades, while evidence is still lacking to support the functionality of majority others. To explore novel lncRNA regulators during osteogenesis, we performed differential expression analysis of RNA-seq data derived from hBMSCs before and after osteogenic induction. AC132217.4 stands out as the most altered lncRNA (100-fold change), which was later confirmed by qRT-PCR, indicating its potential roles in osteogenesis. lncRNA AC132217.4 is spliced from an 844-bp gene segment overlapped with 3'UTR of the *Igf2* genome. Li X. *et al.* reported that AC132217.4 promotes oral squamous cell carcinoma metastasis(26), which is the solely prior publication addressing the biological function of AC132217.4. We found that AC132217.4 over-expression promoted

and its knockdown inhibited osteoblast differentiation of primary hBMSCs. Furthermore, gain-of-function of AC132217.4 *in vivo* promoted the formation of new bone in a murine drill-hole bone healing model. Therefore, we identified lncRNA AC132217.4 as a novel anabolic regulator for osteogenic differentiation both *in vivo* and *in vitro* (Fig. 8).

Biogenesis of AC132217.4 is under cooperative promotion by multiple factors

Biogenesis of lncRNAs is considered to be more precisely controlled than mRNAs, based on their time- and spatial-specific expression pattern. (23–25, 36) Their genome also contains weaker transcription or splicing signals, rendering their low expression in an ‘un-stimulated’ status. (23–25, 36) Consistent with the notion, splicing sites for AC132217.4 also yield a relatively low score based on bioinformatic prediction, indicating it might require extra regulators to increase its expression level. Using RNA-pull-down assay coupled with MS analyses, we identified two splicing factors, HNRNPA1 and SC35, bind to AC132217.4 pre-RNA and cooperatively produce the mature lncRNA. Either HNRNPA1 or SC35 knockdown leads to reduced expression of AC132217.4. Combining bioinformatics and experimental analysis, we also identified the transcription factor ALX1 is regulating AC132217.4 expression. Collectively, our study reveals multiple factors (ALX1, HNRNPA1, SC35) are involved in the biogenesis of AC132217.4 in MSCs. This regulatory pattern might be applicable to other lncRNAs important in MSC differentiation. It might also be an option to modulate their specific biogenesis machinery for therapies designed to target lncRNAs.

ALX1 was characterized as an evolutionarily conserved and crucial regulator of skeletogenesis. Echinoderm phylum is among the most ancient murine organisms first developing endoskeleton; Interestingly, ALX1 is the pivotal transcription factor controlling skeletogenesis program throughout echinoderm phylum. (37, 38) Furthermore, ALX1 was also demonstrated to control embryonic skeleton morphogenesis, especially craniofacial bone development, in higher organisms such as mice, cats, and zebrafish. (39–43) In humans, missense mutations of the ALX1 gene cause type three frontonasal dysplasia (FND3), a rare congenital disorder characterized by abnormality of ocular and craniofacial components. (41, 44, 45) However, the role of ALX1 in MSC osteogenesis remains unclear due to prenatal lethality of ALX1 deficiency in mice. Our study reveals that ALX1 is among the highly up-regulated transcription factors in MSCs during osteogenesis. ALX1 overexpression in MSCs promotes osteoblast differentiation and mineralization. Our study suggests a potential role of ALX1 in postnatal bone formation. Moreover, the downstream effector and signaling pathways of ALX1 in vertebrates remain to be studied, which is vital for understanding the molecular mechanism underlying ALX1's physiological role. Our study also elucidate that ALX1 regulate IGF-AKT signaling by targeting AC132217.4.

Lncrna Ac132217.4 Targets Igf Signaling And Promotes Bone Healing

Combining informatics and experimental analysis, we demonstrate that AC132217.4 promotes osteogenic differentiation through up-regulating IGF2-AKT signaling. We found that AC132217.4 directly increases IGF2 expression at its mRNA level. LncRNA exerts its biological function through different ways, *e.g.*, interacting with DNA, RNA, or proteins(13–16). Our study showed that AC132217.4 localized in the cytoplasm but does not bind with proteins. This indicates that AC132217.4 might regulate IGF2 expression through functioning on its mRNA. This is confirmed by the fact that AC132217.4 overexpression compensates for the effect of RNA synthesis inhibitor on reducing *IGF2* expression.

IGFs (IGF1 and IGF2) are well-known for their role in the 'somatotrophic axis' regulating body growth and bone mass. In this axis, growth hormones induce IGF production by the liver and locally, which play synergistic roles with the growth hormone(30, 31). IGF1 regulating bone growth and integrity has been well-characterized in human and mouse models(30, 31), while IGF2 is much less studied. Generally, currently documented evidence supports the promotional role of IGF2 in skeletal development and osteogenic differentiation. Loss-of-function mutation or decreased transcription of IGF2 in humans is related to Silver Russel Syndrome(46, 47), which is characterized by dwarfism and delayed bone maturation and might be associated with risk of lower bone mass (NIH GARD website). Down-regulating IGF2 expression in mice the human disease phenotype, resulting in retarded growth and lower bone mass, with reduced osteoprogenitors(33). Some other studies also showed a promoting role of exogenous IGF2 in osteogenesis *in vitro* and bone regeneration *in vivo*(33, 48–51). Like IGF1, IGF2 also binds to the IGF1 receptor (IGF1R) or insulin receptor (INSR), which transduces signaling through AKT activation(31). AKT activation promoting osteoblast differentiation and bone healing is extensively studied and well-documented (50, 52–54). Thus, it is reasonable that IGF2 promotes osteoblast differentiation, while its physiological role in adult bone remains to be explored. In this study, we confirmed that the anabolic function of IGF2 in hBMSC osteogenesis through loss-of-function (IGF2 knockdown) and gain-of-function (application of exogenous IGF2) study. Significantly, IGF2 knockdown also impairs the anabolic role of AC132217.4 in osteogenesis. This piece of data further confirms that IGF2 is the indispensable effector of AC132217.4 to regulate osteoblast differentiation.

Moreover, both IGFs are found highly expressed in the fracture callus(55, 56). Altered IGF signaling have also been implicated as reasons for the poor fracture healing(57–61). Besides osteogenesis, IGF also promotes angiogenesis(62), which is another crucial physiological process during fracture healing. Moreover, locally delivered IGFs has a positive effect in multiple fracture models. (63–69) Collectively, IGFs signaling is a critical local regulator to enhance bone repair. In our study, we showed that AC132217.4, which regulates IGF-2 expression, also possess the ability to accelerate bone healing in mice.

In conclusion, our study identified a novel bone anabolic regulator, lncRNA AC132217.4, *in vivo* and *in vitro*. We also revealed that AC132217.4 regulates hBMSC osteogenic differentiation by interacting with IGF2 mRNA to stabilize its expression, which successively induces AKT activation (Fig. 8). Our study also showed that ALX1, SC35, and HNRNPA1 cooperatively regulate AC132217.4 expression (Fig. 8). Our

finding indicates that AC132217.4 might be a novel pharmaceutical target for accelerating bone repair and treating bone disorders.

Declarations

Acknowledgments

This study was supported by grants from China's National Natural Science Foundation (31900513, 81900806, 32070814), and Application Program for Chinese Manned Space Station (YYWT-0901-EXP-06).

Author contributions

Conceptualization, M.W., J.W. and C.Z.; methodology, M.W., J.W. and C.Z.; investigation, C.Z., S.W., E.C.; resources, M.W. and C.Z. writing – original draft, M.W., S.W. and C.Z.; writing – review & editing, M.W. and C.Z.; funding acquisition, M.W. Y.L. and C.Z.; supervision, M.W. and J.W.

Conflicts of Interest

There are no competing financial interests related to the work described.

Data availability statement

All data generated or analysed during this study are included in this published article [and its supplementary information files].

References

1. Donev, R., Newall, A., Thome, J. and Sheer, D. (2007) A role for SC35 and hnRNPA1 in the determination of amyloid precursor protein isoforms. *Mol Psychiatry*, **12**, 681-690.
2. Munir, H. and McGettrick, H.M. (2015) Mesenchymal Stem Cell Therapy for Autoimmune Disease: Risks and Rewards. *Stem Cells Dev*, **24**, 2091-2100.
3. Gonzalez-Rey, E., Gonzalez, M.A., Varela, N., O'Valle, F., Hernandez-Cortes, P., Rico, L., Buscher, D. and Delgado, M. (2010) Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. *Ann Rheum Dis*, **69**, 241-248.
4. Caplan, A.I. and Bruder, S.P. (2001) Mesenchymal stem cells: building blocks for molecular medicine in the 21st century. *Trends Mol Med*, **7**, 259-264.
5. Abarrategi, A., Mian, S.A., Passaro, D., Rouault-Pierre, K., Grey, W. and Bonnet, D. (2018) Modeling the human bone marrow niche in mice: From host bone marrow engraftment to bioengineering approaches. *J Exp Med*, **215**, 729-743.
6. Wu, M., Chen, G. and Li, Y.P. (2016) TGF- β and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease. *Bone research*, **4**, 16009.

7. Gennari, L., Rotatori, S., Bianciardi, S., Nuti, R. and Merlotti, D. (2016) Treatment needs and current options for postmenopausal osteoporosis. *Expert Opin Pharmaco*, **17**, 1141-1152.
8. (2016) Postmenopausal Osteoporosis. *N Engl J Med*, **374**, 1797.
9. Lin, H., Sohn, J., Shen, H., Langhans, M.T. and Tuan, R.S. (2019) Bone marrow mesenchymal stem cells: Aging and tissue engineering applications to enhance bone healing. *Biomaterials*, **203**, 96-110.
10. Zhu, G., Zhang, T., Chen, M., Yao, K., Huang, X., Zhang, B., Li, Y., Liu, J., Wang, Y. and Zhao, Z. (2021) Bone physiological microenvironment and healing mechanism: Basis for future bone-tissue engineering scaffolds. *Bioact Mater*, **6**, 4110-4140.
11. Jiao, H., Xiao, E. and Graves, D.T. (2015) Diabetes and Its Effect on Bone and Fracture Healing. *Curr Osteoporos Rep*, **13**, 327-335.
12. Kline, A.J., Gruen, G.S., Pape, H.C., Tarkin, I.S., Irrgang, J.J. and Wukich, D.K. (2009) Early complications following the operative treatment of pilon fractures with and without diabetes. *Foot & ankle international*, **30**, 1042-1047.
13. Liu, S.J., Dang, H.X., Lim, D.A., Feng, F.Y. and Maher, C.A. (2021) Long noncoding RNAs in cancer metastasis. *Nature reviews. Cancer*.
14. Ulitsky, I. and Bartel, David P. (2013) lincRNAs: Genomics, Evolution, and Mechanisms. *Cell*, **154**, 26-46.
15. Fatica, A. and Bozzoni, I. (2014) Long non-coding RNAs: new players in cell differentiation and development. *Nat Rev Genet*, **15**, 7-21.
16. Hung, T., Wang, Y.L., Lin, M.F., Koegel, A.K., Kotake, Y., Grant, G.D., Horlings, H.M., Shah, N., Umbricht, C., Wang, P. *et al.* (2011) Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. *Nat Genet*, **43**, 621-U196.
17. Gu, H., Li, Z., Lv, X.F., Zhao, A.B., Zhu, M.Y. and Zhang, Y. (2019) LncRNA KCNQ10T1 delayed fracture healing through the Wnt/ β -catenin pathway. *European review for medical and pharmacological sciences*, **23**, 4575-4583.
18. Li, D., Liu, J., Yang, C., Tian, Y., Yin, C., Hu, L., Chen, Z., Zhao, F., Zhang, R., Lu, A. *et al.* (2021) Targeting long noncoding RNA PMIF facilitates osteoprogenitor cells migrating to bone formation surface to promote bone formation during aging. *Theranostics*, **11**, 5585-5604.
19. Liu, Y.B., Lin, L.P., Zou, R., Zhao, Q.H. and Lin, F.Q. (2019) Silencing long non-coding RNA MEG3 accelerates tibia fraction healing by regulating the Wnt/ β -catenin signalling pathway. *Journal of cellular and molecular medicine*, **23**, 3855-3866.
20. Liu, Z.C., Xu, Y.L., Jiang, Y., Liu, Y., Wei, Z.C., Liu, S.G. and Yang, S.J. (2019) Low-expression of lncRNA-ANCR promotes tibial fracture healing via targeting RUNX2. *European review for medical and pharmacological sciences*, **23**, 60-66.
21. Wang, L., Wang, Y.P., Li, Z.Y., Li, Z.Q. and Yu, B. (2015) Differential expression of long noncoding ribonucleic acids during osteogenic differentiation of human bone marrow mesenchymal stem cells. *Int Orthop*, **39**, 1013-1019.

22. Jia, Q., Jiang, W.K. and Ni, L.X. (2015) Down-regulated non-coding RNA (lncRNA-ANCR) promotes osteogenic differentiation of periodontal ligament stem cells. *Arch Oral Biol*, **60**, 234-241.
23. Nojima, T. and Proudfoot, N.J. (2022) Mechanisms of lncRNA biogenesis as revealed by nascent transcriptomics. *Nature reviews. Molecular cell biology*.
24. Quinn, J.J. and Chang, H.Y. (2016) Unique features of long non-coding RNA biogenesis and function. *Nature reviews. Genetics*, **17**, 47-62.
25. Statello, L., Guo, C.J., Chen, L.L. and Huarte, M. (2021) Gene regulation by long non-coding RNAs and its biological functions. *Nature reviews. Molecular cell biology*, **22**, 96-118.
26. Li, X., Ma, C., Zhang, L., Li, N., Zhang, X., He, J., He, R., Shao, M., Wang, J., Kang, L. *et al.* (2017) LncRNAAC132217.4, a KLF8-regulated long non-coding RNA, facilitates oral squamous cell carcinoma metastasis by upregulating IGF2 expression. *Cancer Lett*, **407**, 45-56.
27. Zhang, C., Hong, F.F., Wang, C.C., Li, L., Chen, J.L., Liu, F., Quan, R.F. and Wang, J.F. (2017) TRIB3 inhibits proliferation and promotes osteogenesis in hBMSCs by regulating the ERK1/2 signaling pathway. *Sci Rep-Uk*, **7**.
28. Li, Z. and Helms, J.A. (2021) Drill Hole Models to Investigate Bone Repair. *Methods Mol Biol*, **2221**, 193-204.
29. Chen, E.E.M., Zhang, W., Ye, C.Y.C.Y., Gao, X., Jiang, L.J.L.J., Zhao, T.F.T.F., Pan, Z.J.Z.J. and Xue, D.T.D.T. (2017) Knockdown of SIRT7 enhances the osteogenic differentiation of human bone marrow mesenchymal stem cells partly via activation of the Wnt/beta-catenin signaling pathway. *Cell Death Dis*, **8**.
30. Wang, Y., Bikle, D.D. and Chang, W. (2013) Autocrine and Paracrine Actions of IGF-I Signaling in Skeletal Development. *Bone research*, **1**, 249-259.
31. Yakar, S., Werner, H. and Rosen, C.J. (2018) Insulin-like growth factors: actions on the skeleton. *Journal of molecular endocrinology*, **61**, T115-t137.
32. Shi, Y., Chen, J., Karner, C.M. and Long, F. (2015) Hedgehog signaling activates a positive feedback mechanism involving insulin-like growth factors to induce osteoblast differentiation. *Proceedings of the National Academy of Sciences of the United States of America*, **112**, 4678-4683.
33. Hardouin, S.N., Guo, R., Romeo, P.H., Nagy, A. and Aubin, J.E. (2011) Impaired mesenchymal stem cell differentiation and osteoclastogenesis in mice deficient for Igf2-P2 transcripts. *Development (Cambridge, England)*, **138**, 203-213.
34. Kang, H., Sung, J., Jung, H.M., Woo, K.M., Hong, S.D. and Roh, S. (2012) Insulin-like growth factor 2 promotes osteogenic cell differentiation in the parthenogenetic murine embryonic stem cells. *Tissue engineering. Part A*, **18**, 331-341.
35. Einhorn, T.A. and Gerstenfeld, L.C. (2015) Fracture healing: mechanisms and interventions. *Nature reviews. Rheumatology*, **11**, 45-54.
36. Liu, S.J. and Lim, D.A. (2018) Modulating the expression of long non-coding RNAs for functional studies. *EMBO reports*, **19**.

37. Ettensohn, C.A., Illies, M.R., Oliveri, P. and De Jong, D.L. (2003) Alx1, a member of the Cart1/Alx3/Alx4 subfamily of Paired-class homeodomain proteins, is an essential component of the gene network controlling skeletogenic fate specification in the sea urchin embryo. *Development (Cambridge, England)*, **130**, 2917-2928.
38. Khor, J.M. and Ettensohn, C.A. (2017) Functional divergence of paralogous transcription factors supported the evolution of biomineralization in echinoderms. *eLife*, **6**.
39. Beverdam, A., Brouwer, A., Reijnen, M., Korving, J. and Meijlink, F. (2001) Severe nasal clefting and abnormal embryonic apoptosis in Alx3/Alx4 double mutant mice. *Development (Cambridge, England)*, **128**, 3975-3986.
40. Dee, C.T., Szymoniuk, C.R., Mills, P.E. and Takahashi, T. (2013) Defective neural crest migration revealed by a Zebrafish model of Alx1-related frontonasal dysplasia. *Human molecular genetics*, **22**, 239-251.
41. Iyyanar, P.P.R., Wu, Z., Lan, Y., Hu, Y.C. and Jiang, R. (2022) Alx1 Deficient Mice Recapitulate Craniofacial Phenotype and Reveal Developmental Basis of ALX1-Related Frontonasal Dysplasia. *Frontiers in cell and developmental biology*, **10**, 777887.
42. Lyons, L.A., Erdman, C.A., Grahm, R.A., Hamilton, M.J., Carter, M.J., Helps, C.R., Alhaddad, H. and Gandolfi, B. (2016) Aristaless-Like Homeobox protein 1 (ALX1) variant associated with craniofacial structure and frontonasal dysplasia in Burmese cats. *Developmental biology*, **409**, 451-458.
43. Zhao, Q., Behringer, R.R. and de Crombrughe, B. (1996) Prenatal folic acid treatment suppresses acrania and meroanencephaly in mice mutant for the Cart1 homeobox gene. *Nature genetics*, **13**, 275-283.
44. Pini, J., Kueper, J., Hu, Y.D., Kawasaki, K., Yeung, P., Tsimbal, C., Yoon, B., Carmichael, N., Maas, R.L., Cotney, J. *et al.* (2020) ALX1-related frontonasal dysplasia results from defective neural crest cell development and migration. *EMBO molecular medicine*, **12**, e12013.
45. Uz, E., Alanay, Y., Aktas, D., Vargel, I., Gucer, S., Tuncbilek, G., von Eggeling, F., Yilmaz, E., Deren, O., Posorski, N. *et al.* (2010) Disruption of ALX1 causes extreme microphthalmia and severe facial clefting: expanding the spectrum of autosomal-recessive ALX-related frontonasal dysplasia. *American journal of human genetics*, **86**, 789-796.
46. Masunaga, Y., Inoue, T., Yamoto, K., Fujisawa, Y., Sato, Y., Kawashima-Sonoyama, Y., Morisada, N., Iijima, K., Ohata, Y., Namba, N. *et al.* (2020) IGF2 Mutations. *The Journal of clinical endocrinology and metabolism*, **105**.
47. Yamoto, K., Saitsu, H., Nakagawa, N., Nakajima, H., Hasegawa, T., Fujisawa, Y., Kagami, M., Fukami, M. and Ogata, T. (2017) De novo IGF2 mutation on the paternal allele in a patient with Silver-Russell syndrome and ectrodactyly. *Human mutation*, **38**, 953-958.
48. Yang, L., Li, Y., Gong, R., Gao, M.Q., Feng, C., Liu, T.Y., Sun, Y., Jin, M.Y., Wang, D.W., Yuan, Y. *et al.* (2019) The Long Non-coding RNA-ORLNC1 Regulates Bone Mass by Directing Mesenchymal Stem Cell Fate. *Mol Ther*, **27**, 394-410.

49. Chen, L.A., Jiang, W., Huang, J.Y., He, B.C., Zuo, G.W., Zhang, W.L., Luo, Q., Shi, Q.O., Zhang, B.Q., Wagner, E.R. *et al.* (2010) Insulin-like Growth Factor 2 (IGF-2) Potentiates BMP-9-Induced Osteogenic Differentiation and Bone Formation. *J Bone Miner Res*, **25**, 2447-2459.
50. Ding, W., Li, J., Singh, J., Alif, R., Vazquez-Padron, R.I., Gomes, S.A., Hare, J.M. and Shehadeh, L.A. (2015) miR-30e targets IGF2-regulated osteogenesis in bone marrow-derived mesenchymal stem cells, aortic smooth muscle cells, and ApoE^{-/-} mice. *Cardiovasc Res*, **106**, 131-142.
51. Hamidouche, Z., Fromigue, O., Ringe, J., Haupl, T. and Marie, P.J. (2010) Crosstalks between integrin alpha 5 and IGF2/IGFBP2 signalling trigger human bone marrow-derived mesenchymal stromal osteogenic differentiation. *Bmc Cell Biol*, **11**.
52. Iyer, S., Margulies, B.S. and Kerr, W.G. (2013) Role of SHIP1 in bone biology. *Annals of the New York Academy of Sciences*, **1280**, 11-14.
53. Guntur, A.R. and Rosen, C.J. (2011) The skeleton: a multi-functional complex organ: new insights into osteoblasts and their role in bone formation: the central role of PI3Kinase. *The Journal of endocrinology*, **211**, 123-130.
54. Sun, M.Y., Chi, G.F., Xu, J.J., Tan, Y., Xu, J.Y., Lv, S., Xu, Z.R., Xia, Y.H., Li, L.S. and Li, Y.L. (2018) Extracellular matrix stiffness controls osteogenic differentiation of mesenchymal stem cells mediated by integrin alpha 5. *Stem Cell Res Ther*, **9**.
55. Andrew, J.G., Hoyland, J., Freemont, A.J. and Marsh, D. (1993) Insulinlike growth factor gene expression in human fracture callus. *Calcified tissue international*, **53**, 97-102.
56. Koh, A., Niikura, T., Lee, S.Y., Oe, K., Koga, T., Dogaki, Y. and Kurosaka, M. (2011) Differential gene expression and immunolocalization of insulin-like growth factors and insulin-like growth factor binding proteins between experimental nonunions and standard healing fractures. *Journal of orthopaedic research : official publication of the Orthopaedic Research Society*, **29**, 1820-1826.
57. Chen, Q.Q. and Wang, W.M. (2014) Expression of FGF-2 and IGF-1 in diabetic rats with fracture. *Asian Pacific journal of tropical medicine*, **7**, 71-75.
58. Szczesny, G., Olszewski, W.L., Zagozda, M., Rutkowska, J., Czapnik, Z., Swoboda-Kopeć, E. and Górecki, A. (2011) Genetic factors responsible for long bone fractures non-union. *Archives of orthopaedic and trauma surgery*, **131**, 275-281.
59. Wang, T., Wang, Y., Menendez, A., Fong, C., Babey, M., Tahimic, C.G., Cheng, Z., Li, A., Chang, W. and Bikle, D.D. (2015) Osteoblast-Specific Loss of IGF1R Signaling Results in Impaired Endochondral Bone Formation During Fracture Healing. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*, **30**, 1572-1584.
60. Taniguchi, T., Matsumoto, T. and Shindo, H. (2003) Changes of serum levels of osteocalcin, alkaline phosphatase, IGF-I and IGF-binding protein-3 during fracture healing. *Injury*, **34**, 477-479.
61. Weiss, S., Henle, P., Bidlingmaier, M., Moghaddam, A., Kasten, P. and Zimmermann, G. (2008) Systemic response of the GH/IGF-I axis in timely versus delayed fracture healing. *Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society*, **18**, 205-212.

62. Bach, L.A. (2015) Endothelial cells and the IGF system. *Journal of molecular endocrinology*, **54**, R1-13.
63. Fowlkes, J.L., Thrailkill, K.M., Liu, L., Wahl, E.C., Bunn, R.C., Cockrell, G.E., Perrien, D.S., Aronson, J. and Lumpkin, C.K., Jr. (2006) Effects of systemic and local administration of recombinant human IGF-I (rhIGF-I) on de novo bone formation in an aged mouse model. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*, **21**, 1359-1366.
64. Zhang, X., Xing, H., Qi, F., Liu, H., Gao, L. and Wang, X. (2020) Local delivery of insulin/IGF-1 for bone regeneration: carriers, strategies, and effects. *Nanotheranostics*, **4**, 242-255.
65. Wang, F., Song, Y.L., Li, C.X., Li, D.H., Zhang, H.P., Ma, A.J., Xi, X.Q., Zhang, N., Wang, B.G., Wang, Y. *et al.* (2010) Sustained release of insulin-like growth factor-1 from poly(lactide-co-glycolide) microspheres improves osseointegration of dental implants in type 2 diabetic rats. *European journal of pharmacology*, **640**, 226-232.
66. Locatelli, V. and Bianchi, V.E. (2014) Effect of GH/IGF-1 on Bone Metabolism and Osteoporosis. *International Journal of Endocrinology*, **2014**, 235060.
67. Chen, L., Jiang, W., Huang, J., He, B.C., Zuo, G.W., Zhang, W., Luo, Q., Shi, Q., Zhang, B.Q., Wagner, E.R. *et al.* (2010) Insulin-like growth factor 2 (IGF-2) potentiates BMP-9-induced osteogenic differentiation and bone formation. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*, **25**, 2447-2459.
68. Majidinia, M., Sadeghpour, A. and Yousefi, B. (2018) The roles of signaling pathways in bone repair and regeneration. *Journal of cellular physiology*, **233**, 2937-2948.
69. Lu, S., Lam, J., Trachtenberg, J.E., Lee, E.J., Seyednejad, H., van den Beucken, J., Tabata, Y., Wong, M.E., Jansen, J.A., Mikos, A.G. *et al.* (2014) Dual growth factor delivery from bilayered, biodegradable hydrogel composites for spatially-guided osteochondral tissue repair. *Biomaterials*, **35**, 8829-8839.

Figures

Figure 1

AC132217.4 promoted osteogenic differentiation of human bone mesenchymal stem cells (hBMSCs). (A) Differential expression of LncRNAs during the process of hBMSCs osteogenesis. (B) Expression of AC132217.4 increased with osteogenic induction. (C, D) Expression of osteoblast marker genes in osteogenic differentiated hBMSC with or without AC132217.4 overexpression is detected by (C) quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and (D) western blotting. (E-G) Osteoblast maturation and mineralization of osteogenic differentiated hBMSC with or without AC132217.4 overexpression are analyzed by alkaline phosphatase (ALP) stain (E), quantification of ALP activity (F), and Alizarin Red stain (G). (J-L) Osteoblast maturation and mineralization of osteogenic differentiated hBMSC with or without AC132217.4 knockdown are analyzed by ALP stain (J), ALP activity

quantification (K), and Alizarin Red stain (L). CTR, Control hBMSC; ACH, AC132217.4 over-expressing hBMSC; shCTR, control-shRNA transfected BMSCs; AC shRNA, AC132217.4-shRNA transfected hBMSCs. Scale:50um. Data are expressed as mean $\pm$ SD; $N \geq 3$; * $p < 0.05$, ** $p < 0.01$.

Figure 2

AC132217.4 increased insulin growth factor 2 (IGF2) expression. (A) RNA pull-down was performed using synthesized biotin-conjugated AC132217.4 pre-RNA or lncRNA and cell lysates from osteogenic differentiated hBMSCs. (B, C) Proteins obtained from RNA pull-down in (A) were further analyzed using silver stain on the SDS PAGE gel (B) and Mass spectrometry (C). All proteins binding with AC132217.4 lncRNA found by MS were listed in (C). (D) Fluorescence in situ hybridization (FISH) and (E) cell fractionation analysis of AC132217.4 subcellular location. (F, G) Expression of IGF2 during osteogenic induction was analyzed using (F) quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and (G) western blotting. (H) Expression of IGF2 mRNA in osteogenic differentiated hBMSC with or w/o 5 μ g/ml actinomycin D (ActD) treatment for the indicated time. (I, J) Expression of IGF2 in osteogenic differentiated hBMSC with or w/o AC132217.4 over-expression or knockdown was determined by qPCR (I) and western blot (J). (K) Concentration of secreted IGF2 in control, AC132217.4 over-expressing, or AC132217.4 knockdown hBMSC was determined by Elisa. CTR, Control hBMSC; ACH, AC132217.4 over-expressing hBMSC; shCTR, control-shRNA transfected BMSCs; AC shRNA, AC132217.4-shRNA transfected hBMSCs. Scale: 20um. Data are expressed as mean $\pm$ SD; $N \geq 3$; * $p < 0.05$, ** $p < 0.01$.

Figure 3

AC132217.4 promoted osteogenic differentiation of human bone mesenchymal stem cells (hBMSCs) through insulin growth factor 2 (IGF2)/AKT signalling. (A, B) Expression of osteoblast marker genes in osteogenic differentiated hBMSC with or w/o IGF2 knockdown is detected by (A) quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and (B) western blotting. (C-E) Osteoblast maturation and mineralization of differentiated hBMSC with or w/o IGF2 knockdown are analyzed by alkaline phosphatase (ALP) stain (C), quantification of ALP activity (D), and Alizarin Red stain (E). (F, G) IGF2 knockdown compromised the promoting effect of AC132217.4 overexpression on the expression of osteoblast marker genes, as detected by (F) qRT-PCR and (G) western blotting. (H-J) IGF2 knockdown compromised the promoting effect of AC132217.4 overexpression on osteoblast maturation and function, as detected by (H) ALP stain, (I) quantification of ALP activity, and (J) Alizarin red stain. (K) Western blot to analyze AKT phosphorylation in AC132217.4 overexpressed and knockdown cell. (L) Knockdown of IGF2 abolished the effect of AC132217.4 over-expression on AKT phosphorylation, as detected by western blot. CTR, Control hBMSC; ACH, AC132217.4 over-expressing hBMSC; shCTR, control-shRNA transfected BMSCs; AC shRNA, AC132217.4-shRNA transfected hBMSCs. IGF2 shRNA, IGF2-shRNA transfected hBMSCs. Scale: 50um. Data are expressed as mean $\pm$ SD; $N \geq 3$; * $p < 0.05$, ** $p < 0.01$.

Figure 4

SC35 and heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1) regulated AC132217.4 splicing. (A, B) The flanking primers to identify AC132217.4 pre-RNA and mature lncRNA were indicated in AC132217.4 splicing-mode diagram (A) and confirmed by reverse transcription-polymerase chain reaction (RT-PCR) (B). (C) RT-PCR to detect AC132217.4 expression in hBMSC overexpressing wild-type or splicing site mutated AC132217.4 pre-RNA. (D) A list of proteins was identified binding with AC132217.4 pre-RNA using mass spectrometry coupled with RNA pull-down. (E) RNA pull-down coupled with western blotting verified the binding of AC132217.4 pre-RNA with HNRNPA1 and SC35. (F) Western blotting confirms HNRNPA1 and SC35 knockdown in hBMSCs by their siRNA, respectively. (G) Mature AC132217.4 lncRNA produced from its pre-RNA is decreased in the presence of HNRNPA1 or SC35 siRNA, as detected by RT-PCR.

Figure 5

ALX1 promoted IGF2 production by enhancing AC132217.4 gene transcription. (A) Differential expression analysis of transcription factors in human bone mesenchymal stem cells (hBMSCs) before and after osteogenic-differentiation. (B, C) Prediction of ALX1 binding sites on the AC132217.4 promoter using PROMO. (D, F) mRNA level of ALX1, AC132217.4 and IGF2 in control, ALX1-knockdown (D) and ALX1-overexpressing (F) hBMSC, as detected by quantitative reverse transcription-polymerase chain reaction (q-RT-PCR). (E, G) Western blot analysis of IGF2 and ALX1 protein level of control, ALX1-knockdown (E), and ALX1-overexpressing (G) hBMSCs. (H) Wild-type (WT) or mutated (MUT) AC132217.4 promoter was constructed before a firefly luciferase CDS in the pGL3-basic vector. (I) Firefly luciferase activity driven by WT or MUT AC132217.4 promoter, with or w/o ALX1 overexpression, was detected and normalized with Renilla luciferase activity. (J) Secreted IGF2 concentration in control, ALX1-knockdown, and ALX1-overexpressing hBMSC were detected by ELISA. (K) AC132217.4 knockdown abolishes the effect of ALX1 overexpression on IGF2 production, as detected by western blot hBMSCs. ALX1i-1/2, ALX1-shRNA transfected hBMSC; CTR shRNA, control-shRNA transfected hBMSCs; CTR, control hBMSCs; ALX1H, ALX1-overexpressing hBMSCs; AC shRNA, AC132217.4-shRNA transfected hBMSCs. Scale: 50um. Data are expressed as mean $\pm$ SD; $N \geq 3$; * $p < 0.05$, ** $p < 0.01$.

Figure 6

ALX1 promoted osteoblast differentiation by AC132217.4-IGF2 signaling. (A,B) Osteoblast differentiation and maturation of control and ALX1 over-expressed hBMSCs with or without AC132217.4 or IGF2 knockdown is detected by ALP stain (A), alizarin red stain (A) and ALP activity (B). (C,D) Osteoblast

marker gene expression in control and ALX1 over-expressed hBMSCs with or without AC132217.4 or IGF2 knockdown was detected by qRT-PCR (C) and western blot (D).

Figure 7

AC132217.4 overexpression promoted bone healing in mice. (A) The timeline of the generation of a murine drill-hole model and the local injection of the lentivirus overexpressing GFP or GFP+AC132217.4. (B) Tracing of in-vivo lentivirus transfection using immunofluorescence staining with a GFP antibody. Scale: 25um. (C) The reconstructed three-dimensional images from μ -CT analysis of the bone healing sites in 1- and 2-weeks post-surgery (D). Quantification of bone volume (BV, mm³), bone volume/total volume (BV/TV, %) and bone mineral density (BMD), based on μ -CT analysis in c. (E-G) Hematoxylin-eosin (H&E) stain (E), Safranin O stain (F), and TRAP stain (G) of the paraffin sections prepared from the injured bone 1- and 2-weeks post-surgery. (E-G) Scale: 50um.

Figure 8

AC132217.4 promotes osteogenesis and bone healing. A novel lncRNA in mesenchymal stem cells, AC132217.4, is identified to promote osteogenesis and bone regeneration. During osteogenesis of mesenchymal stem cells, the transcription factor ALX1 and the splicing factors HnrnpA1 and SC35 enhance the production of AC132217.4. Afterward, AC132217.4 binds to *IGF2* mRNA and stabilizes its expression to enhance IGF2/AKT signaling and osteoblast formation.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [supplementV9.doc](#)